Focal Therapy of Prostate Cancer—The Challenge
The ideal utilization of focal therapy is to treat a smaller prostate cancer in which you can ablate, excise, or render inconsequential a tumor that affects a relatively small fraction of the gland.
Journal Name: Clinical Chemistry and Laboratory Medicine (CCLM) Issue: Ahead of print
Publication date: Available online 12 November 2019Source: European UrologyAuthor(s): Guillaume Ploussard
ConclusionsFKBP9 may be a cancer promoter that enhances PCa progression, and the level of FKBP9 may be used as an independent precursor of PCa patients.
ConclusionThe major findings of this meta-analysis suggested that IL-8 rs4073 polymorphism is significantly associated with risk of prostate cancer.
Publication date: Available online 11 November 2019Source: Biosensors and BioelectronicsAuthor(s): Parham Ghassemi, Xiang Ren, Brittni M. Foster, Bethany A. Kerr, Masoud AgahAbstractCirculating tumor cells (CTCs) in blood can provide valuable information when detecting, diagnosing, and monitoring cancer. This paper describes a system that consists of a constriction-based microfluidic sensor with embedded electrodes that can detect and enumerate cancer cells in blood. The biosensor measures impedance in terms of magnitude and phase at multiple frequencies as cells transit through the constriction channel. Cancer cells defor...
Conclusion: These findings suggest that a pro-inflammatory diet is a risk factor for prostate cancer and also can have the impact on body composition.
ConclusionsThe intervention was associated with increased patient knowledge. Data from this pilot have guided the development of a larger scale randomized clinical trial to improve decision quality in men with prostate cancer being treated in community settings.
Prostate Cancer and Prostatic Diseases, Published online: 12 November 2019; doi:10.1038/s41391-019-0185-7Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy
Radio-recurrent prostate cancer is typically detected by a rising PSA and may reflect local or distant disease. PET radiotracers targeting PSMA such as 18F-DCFPyL have shown promise in restaging men with recurrent disease post-prostatectomy but are less well characterized in the setting of radio-recurrent disease.
Conditions: Castration Levels of Testosterone; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Prostate Carcinoma Metastatic in the Bone; Stage IVB Prostate Cancer AJCC v8 Interventions: Drug: Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981; Biological: Nivolumab Sponsors: Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI) Not yet recruiting